Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
6-phosphogluconate dehydrogenase (6PGDH) is an enzyme that catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose-5-phosphate and CO₂, with concomitant reduction of NADP⁺ to NADPH. It is the third step in the oxidative branch of the pentose phosphate pathway (PPP), which is crucial for generating NADPH for reductive biosynthesis and antioxidant defense, and for producing ribulose-5-phosphate for nucleotide synthesis. 6PGDH is a homodimer expressed in most tissues, particularly those with high biosynthetic or antioxidant demands. Mutations can cause 6-phosphogluconate dehydrogenase deficiency, leading to hemolytic anemia. It also regulates metabolism in regulatory T cells (Tregs), implicating it as a metabolic checkpoint relevant to immunotherapy applications.
Inhibition of 6-phosphogluconate dehydrogenase leads to reduced Treg suppressive function and shifts toward pro-inflammatory phenotypes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 6-phosphogluconate dehydrogenase (6PGDH).